Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alnylam Pharmaceuticals (ALNY) PT Trimmed to $95 at Chardan Capital Markets
May 5, 2017 10:07 AM EDTChardan Capital Markets lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $95.00 (from $97.00) while maintaining a Buy rating following Q1 results.
Analyst Madhu Kumar commented, "Alnylam's lead asset, patisiran, a RNAi drug targeting transthyretin (TTR), is currently in the phase III APOLLO... More
Alnylam Pharma (ALNY) Tops Q1 EPS by 1c
May 5, 2017 8:01 AM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.25), $0.01 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $19 million versus the consensus estimate of $23.65 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More